Anica Hogner

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.

Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.

Journal: JAMA network open
Published: January 23, 2024

Immunotherapy as a new perspective for the therapy of esophageal cancer.

Immunotherapy as a new perspective for the therapy of esophageal cancer.

Journal: Innovative surgical sciences
Published: March 19, 2023

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2022

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy.

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy.

Journal: Current oncology (Toronto, Ont.)
Published: February 06, 2022

Prognostic Relevance of Weight and Weight Loss during Multimodal Therapy for Oesophagogastric Tumours.

Prognostic Relevance of Weight and Weight Loss during Multimodal Therapy for Oesophagogastric Tumours.

Journal: Current oncology (Toronto, Ont.)
Published: February 02, 2022

Immunotherapy in Gastric Cancer.

Immunotherapy in Gastric Cancer.

Journal: Current oncology (Toronto, Ont.)
Published: January 30, 2022

Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.

Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.

Journal: International journal of cancer
Published: May 26, 2021

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma.

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 12, 2021

Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.

Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.

Journal: International journal of molecular sciences
Published: May 16, 2018

PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.

PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.

Journal: Urologic oncology
Published: June 19, 2017

You are not alone.

You are not alone.

Journal: Acta physiologica (Oxford, England)
Published: November 30, 2016

Myoglobin facilitates angiotensin II-induced constriction of renal afferent arterioles.

Myoglobin facilitates angiotensin II-induced constriction of renal afferent arterioles.

Journal: American journal of physiology. Renal physiology
Published: July 05, 2016
Showing 1-12 of 14

Last Updated: 09/26/2026